Ascentage Pharma Group International
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASPHF research report →
About the company
Ascentage Pharma Group International (ASPHF) is a clinical-stage biotechnology firm that develops novel therapeutic agents. Its primary focus areas include oncological conditions, chronic hepatitis B (HBV), and age-related diseases, with operations concentrated in the United States and Mainland China. A cornerstone of its pipeline is HQP1351, a BCR-ABL inhibitor specifically engineered to combat BCR-ABL mutants, including those bearing the challenging T315I mutation.
- CEO
- Dajun Yang
- IPO
- 2021
- Employees
- 567
- HQ
- Suzhou, CN
Price Chart
- Market Cap
- $1.69B
- P/E
- -9.57
- P/S
- 20.83
- P/B
- 8.90
- EV/EBITDA
- -10.17
- Div Yield
- 0.00%
- Gross Margin
- 84.09%
- Op Margin
- -210.40%
- Net Margin
- -216.71%
- ROE
- -123.74%
- ROIC
- -33.68%
- Revenue
- $559.30M · -42.97%
- Net Income
- $-1,210,698,288 · -198.62%
- EPS
- $-3.43 · -150.36%
- Op Income
- $-1,180,905,484
- FCF YoY
- -785.91%
- 52W High
- $10.65
- 52W Low
- $4.53
- 50D MA
- $6.13
- 200D MA
- $8.06
- Beta
- 0.65
- Avg Volume
- 4
Get TickerSpark's AI analysis on ASPHF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ASPHF coverage
Recent articles, reports, and earnings notes.
No research on ASPHF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ASPHF report →Similar companies
Peers in the same neighborhood.